Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 29, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,987,103

« Back to Dashboard

Which drugs does patent 6,987,103 protect, and when does it expire?

Patent 6,987,103 protects SYNRIBO and is included in one NDA. There has been one Paragraph IV challenge on Synribo.

This patent has seventeen patent family members in twelve countries.

Summary for Patent: 6,987,103

Title:Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
Abstract: The present invention concerns a method of treating chronic myelogenous leukemia, a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia in a subject animal, comprising: (a) selecting or identifying an animal suffering from chronic myelogenous leukemia or a related myeloproliferative disorder and showing resistance or intolerance to treatment with STI571; and (b) administering to the animal homoharringtonine. In a preferred embodiment, the animal is a human being.
Inventor(s): Robin; Jean-Pierre (Charlottesville, VA), Mahon; Francois-Xavier (Bordeaux, FR), Maisonneuve; Herve (La Roche sur Yon, FR), Maloisel; Frederick (Illkirch Graffenstaden, FR), Blanchard; Julie (Rouillon, FR)
Assignee: Stragen Pharma S.A. (Geneva, CH)
Application Number:10/397,267
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ivax Intl
omacetaxine mepesuccinate
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,987,103

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus1109799► Subscribe
Canada2459822► Subscribe
Cyprus1112817► Subscribe
Germany60234708► Subscribe
Denmark1443933► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus